Etranacogene Dezaparvovec-Drlb

Introduction Overview

Generic Name

etranacogene dezaparvovec-drlb

Brand Name

Hemgenix

Dosage Form

suspension, for intravenous infusion

Drug Class

Miscellaneous coagulation modifiers

Pharmacokinetics

Absorption:
Hemgenix is administered as a suspension via a single intravenous infusion, enabling direct systemic delivery of the recombinant adeno-associated virus vector carrying the Factor IX gene. Given the intravenous route, absorption through traditional gastrointestinal pathways is bypassed, resulting in immediate systemic availability of the vector. The vector disperses via the bloodstream to the liver, the target site of gene expression.

Distribution:
Following intravenous infusion, etranacogene dezaparvovec-drlb is rapidly distributed to hepatocytes where the viral vector delivers the therapeutic gene. The biodistribution studies reveal predominant localization in liver tissues, the site of endogenous Factor IX synthesis. Minimal distribution to extrahepatic tissues reduces off-target effects. The vector’s tropism for liver cells facilitates targeted transduction and efficient gene expression.

Metabolism:
The therapeutic utilizes an adeno-associated viral vector that remains episomal within hepatocytes and does not integrate into the host genome, thus evading traditional metabolic degradation pathways. The expressed Factor IX protein undergoes normal hepatic post-translational modifications before secretion into circulation. Vector particles are gradually cleared by host immune mechanisms and intracellular degradation processes, with the transgene-mediated protein production sustained for years.

Elimination:
Clearance of the vector itself occurs primarily via nuclease-mediated degradation within cells and immune clearance, with no renal or hepatic elimination akin to small molecule drugs. The expressed Factor IX protein exhibits a half-life consistent with endogenous FIX, contributing to long-term hemostatic correction. Liver enzyme monitoring post-administration is essential, as transient hepatic enzyme elevations have been observed, likely due to immune response to vector or transduced cells.

Dosage Forms

Available Dosage Forms:
- Suspension for intravenous infusion.

Dosages for Adults and Adolescents:
- Single administration of 2 x 10^13 genome copies (gc) per kilogram of body weight.
- The dose is administered as an intravenous infusion after dilution with 0.9% normal saline.
- Infusion rate is maintained at a constant 500 mL/hour (8 mL/min) and adjusted based on patient tolerance.

Specific Patient Populations:
- Indicated for adults with hemophilia B who are currently using Factor IX prophylaxis therapy or have a history/current life-threatening hemorrhage or repeated serious spontaneous bleeding episodes.
- Not intended for administration in women or pediatric populations due to lack of safety and efficacy data.
- Pre-infusion screening includes testing for Factor IX inhibitors; patients with persistent inhibitors are excluded.
- Liver function evaluation is mandatory before and periodically after infusion to monitor hepatic safety.

Clinical Guidance:
- Hemgenix is a one-time gene therapy; repeat dosing is not recommended.
- Post-infusion monitoring includes at least 3 hours observation for infusion reactions.
- Weekly liver enzyme tests for 3 months post-infusion and extended hepatic monitoring up to 5 years if preexisting risk factors for liver cancer are present.

Mechanism Of Action

Hemgenix operates as a pioneering gene therapy designed to address hemophilia B at its molecular root by delivering a functional copy of the Factor IX gene directly into hepatocytes. The therapeutic employs a recombinant adeno-associated virus serotype, which acts as a vector to transport the DNA encoding the Factor IX protein specifically to liver cells, the natural site of clotting factor production.

Once inside the hepatocytes, the delivered gene remains episomal and exploits the host cell's transcriptional machinery to synthesize functional Factor IX protein. This approach sidesteps the limitations of exogenous Factor IX replacement by enabling sustained endogenous production, effectively raising plasma Factor IX levels to physiologically meaningful ranges, thereby facilitating coagulation and reducing bleeding episodes.

The viral vector's high liver tropism ensures targeted localization and minimizes systemic exposure, optimizing efficacy while limiting off-target effects and immunogenicity. Unlike traditional therapies requiring frequent infusions, Hemgenix's gene transfer strategy provides prolonged therapeutic benefit from a single administration.

Clinical studies have demonstrated durable expression of Factor IX following a single infusion, significantly decreasing annualized bleeding rates and reducing or eliminating the need for prophylactic Factor IX concentrates. This mechanism represents a paradigm shift for hemophilia management, transforming a chronic replacement therapy into a potential long-lasting genetic correction. Comparative therapies such as recombinant Factor IX concentrates focus on transient protein replacement, whereas Hemgenix seeks to restore endogenous production enabling sustained hemostatic correction.

Pharmacological Actions

Provides a one-time gene therapy approach for sustained expression of functional Factor IX protein in hemophilia B patients.
Utilizes an adeno-associated viral vector to deliver the Factor IX gene specifically to liver hepatocytes.
Leads to endogenous production of coagulation Factor IX, enhancing blood clotting capabilities.
Reduces frequency and severity of bleeding episodes associated with congenital Factor IX deficiency.
Avoids repeated intravenous infusions typical of conventional replacement therapy.
Demonstrates liver tropism providing targeted gene delivery and minimizing off-target effects.
Initiates durable transgene expression lasting years post single administration.
Modulates hemostasis by restoring deficient coagulation pathways without direct coagulation factor administration.
Potentially reduces dependency on prophylactic intravenous clotting factor replacement therapies.
May improve quality of life in hemophilia B patients by decreasing spontaneous hemorrhages.
Employs episomal vector DNA, avoiding insertional mutagenesis risk associated with integrating vectors.
Triggers immune responses that require monitoring, particularly of liver enzymes.
Used exclusively in adult populations due to limited pediatric data.
Requires pre-treatment screening for Factor IX inhibitors to ensure therapeutic efficacy.

Therapeutic Or Clinical Uses

Treatment of adult patients with hemophilia B characterized by congenital Factor IX deficiency.
Reduction of annualized bleeding rates in adults with severe or moderate hemophilia B.
Alternative to frequent prophylactic administration of exogenous Factor IX concentrate.
Management of patients with history of life-threatening hemorrhages or frequent spontaneous bleeding.
Gene therapy for sustained endogenous production of coagulation Factor IX protein.
Adjunct in treatment plans aiming to improve long-term hemostatic control in hemophilia B.
Improvement of clinical outcomes by minimizing joint damage caused by repeated bleeding.
Potential reduction in the need for blood product transfusions and hospitalizations.
Use in patients without detectable inhibitors to Factor IX to ensure response to gene therapy.
Monitoring tool for evaluation of liver function as a safety parameter in treatment protocols.
Therapy designed to maintain therapeutic Factor IX levels over an extended time frame.
Treatment option providing a one-time administration to alleviate chronic disease burden.
Used primarily in those currently receiving Factor IX prophylaxis or with significant bleeding history.
Considered in patients unsuitable or unwilling to continue lifelong replacement therapy.
A gene-based curative approach in progressive bleeding disorders linked to Factor IX deficiency.

Side Or Adverse Effects

Elevation of liver enzymes, indicating possible hepatocellular injury or immune response.
Infusion-related reactions including chest tightness, headaches, abdominal pain, and lightheadedness.
Flu-like symptoms such as shivering, flushing, rash, and fatigue.
Nausea and general feelings of malaise post administration.
Potential for transient elevated blood pressure during or after infusion.
Headache, which is among the most frequently reported adverse events.
Infusion reactions may require slowing or temporary interruption of the infusion.
Risk of immune-mediated liver inflammation necessitating close monitoring.
No current reports of severe hypersensitivity or anaphylaxis, but observed during infusion.
Possible development of Factor IX inhibitors if not screened appropriately prior to therapy.
Post-therapy hepatic health surveillance essential due to risk of chronic liver complications.
Unknown long-term safety profile necessitates ongoing pharmacovigilance and registry data.
Potential for subclinical effects on liver function requiring periodic liver imaging and labs.
Information lacking on effects during pregnancy; therapy not intended for female patients.
Rare but serious adverse events may emerge with broader clinical use; vigilance required.

Precautions

Screen patients for Factor IX inhibitors prior to administration; contraindicated if inhibitors present.
Assess liver function thoroughly before infusion with ongoing hepatic enzyme monitoring for 3 months post-treatment.
Administer only once; repeated dosing safety and efficacy not established.
Monitor patients closely for at least 3 hours during and following infusion due to risk of infusion reactions.
Use cautiously in patients with preexisting liver disease; ongoing liver health evaluation recommended for 5 years if risk factors exist.
Women are not candidates for this therapy; safety in pregnancy and breastfeeding is undetermined.
Avoid blood, organ, or tissue donation after receiving Hemgenix due to unknown shedding duration.
Inform healthcare professionals of all medications, supplements, and herbal products to monitor potential interactions.
Be prepared to manage infusion-related adverse effects, including slowing or halting infusion.
Ensure patient compliance with post-infusion monitoring and laboratory assessments.
Educate patients on recognizing and promptly reporting symptoms related to infusion reactions or hepatic dysfunction.
Consider immunosuppressive therapy if significant liver enzyme elevations or immune responses develop.
The therapy is not a vaccine and does not prevent bleeding from causes other than Factor IX deficiency.
Storage and preparation require adherence to sterile technique and handling instructions to maintain vector integrity.
Maintain close follow-up to assess long-term efficacy and safety outcomes, including Factor IX activity levels.

Warnings

Risk of serious infusion-related reactions, including hypersensitivity and anaphylactoid symptoms.
Potential for liver enzyme elevations, which may indicate liver injury requiring medical intervention.
Not recommended for use in females or pediatric patients due to lack of clinical data.
Potential shedding of viral vector components into bodily fluids; avoid donation of blood, tissues, or organs post-treatment.
Immune responses against the vector or transduced cells may reduce therapy effectiveness or cause adverse reactions.
Monitor liver function frequently post-therapy; elevated liver enzymes may necessitate corticosteroid treatment.
Infusion must occur under medical supervision with readiness to manage acute adverse reactions.
Unknown long-term oncogenic risk; patients with prior liver cancer risk factors require extended surveillance.
Contraindicated in patients with positive Factor IX inhibitors to avoid lack of efficacy and adverse immune responses.
Avoid use in combination with immunomodulatory drugs unless clinically justified.
Therapy is a one-time treatment; re-administration risks and benefits have not been established.
Potential impact on immune system components and autoimmunity has not been fully characterized.
Use caution in patients with unstable hepatic or systemic conditions that may exacerbate adverse effects.
Risk-benefit analysis required due to high cost and specialized therapeutic profile.
Healthcare providers should stay informed on emerging safety data and report adverse events to regulatory agencies.

Contraindication

Known hypersensitivity to components of Hemgenix or the viral vector.
Presence of Factor IX inhibitors confirmed by two consecutive positive tests pre-infusion.
Women who are pregnant, breastfeeding, or of reproductive potential due to unknown safety profile.
Patients with active liver disease or severe hepatic impairment without adequate stabilization.
Individuals with a history of severe allergic reaction to gene therapy agents or similar biological products.
Patients currently participating in other investigational drug trials where interactions may confound safety.
Known immunodeficiency conditions that could impair vector clearance or transgene expression.
Individuals unable or unwilling to comply with monitoring requirements and follow-up visits.
Use in pediatric patients has not been studied and is therefore contraindicated.
Patients with a history of liver malignancy or known hepatocellular carcinoma unless carefully evaluated.
Contraindicated in patients with uncontrolled systemic infections or inflammation.
Presence of antibodies against the viral vector at levels that would neutralize vector efficacy.
Patients with coagulation disorders other than hemophilia B with Factor IX deficiency.
Individuals with contraindications to intravenous infusion or components of the infusion solution.
Patients with conditions leading to impaired clearance or increased susceptibility to vector-related toxicities.

Drug Interactions

Potential interactions with immunosuppressants, which may alter the immune response to the viral vector.
Concomitant use of anticoagulants may affect bleeding risk and complicate assessment of therapy efficacy.
Interactions with hepatotoxic drugs could exacerbate liver enzyme elevations post-therapy.
Caution advised when using agents that modulate liver enzyme activity or hepatic blood flow.
Concurrent medications altering immune function may impact vector transduction and persistence.
Possible interference with diagnostic assays for Factor IX levels due to endogenous and transgene protein overlap.
Interactions with drugs affecting coagulation pathways must be closely monitored to avoid bleeding or thrombosis.
Herbal supplements with immunomodulatory properties could unpredictably influence therapy outcomes.
Use with drugs causing renal impairment may modify clearance pathways of coagulation factors.
Drug regimens influencing cytokine release or immune activation may increase the risk of infusion reactions.
Co-administration with vaccines has unknown effects on vector immunity or efficacy.
Medications that induce or inhibit cytochrome P450 enzymes may affect hepatic metabolism indirectly related to Factor IX synthesis.
Avoid starting new systemic therapies during the monitoring period to reduce confounding adverse effect assessments.
Agents that affect vascular integrity or platelet function require careful evaluation before use concurrently.
Potential drug–drug interactions remain under investigation due to the novel nature of gene therapy.

Preparations Of The Drug

Hemgenix is provided as a sterile suspension for intravenous infusion in a single-use vial.
Supplied in a formulation compatible with dilution in 0.9% normal saline prior to administration.
Requires preparation under aseptic conditions to maintain vector stability and prevent contamination.
Storage conditions necessitate refrigeration at 2°C to 8°C (36°F to 46°F); do not freeze.
The suspension should be gently mixed prior to dilution to ensure homogeneity of viral vector concentration.
Must be administered promptly after preparation to preserve viral particle viability and efficacy.
Single-dose vial format corresponds to weight-adjusted dosing, limiting preparation errors.
Discard any unused portion after infusion; no preservative agents are included.
Infusion set up includes standard intravenous tubing with appropriate filters as per institutional protocols.
Instructions specify a constant infusion rate of 500 mL/hour (8 mL/min) after dilution.
Healthcare providers should be trained in gene therapy preparation and administration procedures.
Preparation should occur in controlled environments such as hospital pharmacies or infusion centers with specialized facilities.
Patient identification and dose verification protocols must be strictly followed due to personalized dosing.
All steps of handling from vial puncture to infusion require documentation to maintain chain of custody and safety.
Disposal of materials must comply with biosafety and biohazard regulations due to viral vector nature.